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Abstract
The HIV envelope (Env) glycoprotein mediates membrane fusion through sequential interactions with CD4 and coreceptors,
followed by the refolding of the transmembrane gp41 subunit into the stable 6-helix bundle (6HB) conformation. Synthetic
peptides derived from the gp41 C-terminal heptad repeat domain (C-peptides) potently inhibit fusion by binding to the
gp41 pre-bundle intermediates and blocking their conversion into the 6HB. Our recent work revealed that HIV-1 enters cells
by fusing with endosomes, but not with the plasma membrane. These studies also showed that, for the large part, gp41 pre-
bundles progress toward 6HBs in endosomal compartments and are thus protected from external fusion inhibitors. Here, we
examined the consequences of endocytic entry on the gp41 pre-bundle exposure and on the virus’ sensitivity to C-peptides.
The rates of CD4 and coreceptor binding, as well as the rate of productive receptor-mediated endocytosis, were measured
by adding specific inhibitors of these steps at varied times of virus-cell incubation. Following the CD4 binding, CCR5-tropic
viruses recruited a requisite number of coreceptors much faster than CXCR4-tropic viruses. The rate of subsequent uptake of
ternary Env-CD4-coreceptor complexes did not correlate with the kinetics of coreceptor engagement. These measurements
combined with kinetic analyses enabled the determination of the lifetime of pre-bundle intermediates on the cell surface.
Overall, these lifetimes correlated with the inhibitory potency of C-peptides. On the other hand, the basal sensitivity to
peptides varied considerably among diverse HIV-1 isolates and ranked similarly with their susceptibility to inactivation by
soluble CD4. We conclude that both the longevity of gp41 intermediates and the extent of irreversible conformational
changes in Env upon CD4 binding determine the antiviral potency of C-peptides.
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Introduction
HIV Env-induced fusion between the viral and cellular
membrane progresses through a series of steps that begin with
binding of the gp120 subunit to CD4. This step results in the
formation of the gp120 bridging sheet which, along with the third
hypervariable loop (V3 loop), forms the coreceptor binding site
(reviewed in [1]). The recruitment of coreceptors, CCR5 or
CXCR4, by Env-CD4 complexes initiates gp41 refolding that
progresses through a pre-bundle intermediate, in which the gp41
N- and C-terminal heptad repeat domains (N-HR and C-HR,
respectively) are exposed [2–5]. The heptad repeat domains
ultimately coalesce into the stable post-fusion conformation
referred to as the 6-helix bundle (6HB). The 6HB is formed by
an antiparallel association of the trimeric N-HR domain (coiled
coil) with three peripheral C-HR domains (reviewed in [6]). In a
pre-bundle conformation, gp41 is susceptible to inhibition by
synthetic peptides derived from its C-HR domain (hereafter
referred to as C-peptides). These peptides bind to the comple-
mentary N-HR region and block HIV fusion by preventing the
formation of 6HBs [6–8].
The kinetics of HIV fusion and the progression of gp41 pre-
bundles to the 6HB has been studied in a cell-cell fusion model
[4,9–13]. Biochemical studies using a tagged C-peptide showed
that, depending on the virus strain, the gp41 coiled coils can be
exposed as early as upon CD4 binding [2]. Once formed, the pre-
bundles are thought to persist for a couple of minutes prior to
converting into the 6HB [14]. Using a real-time cell-cell fusion
assay, we observed that small fusion pores collapsed soon after the
addition of C-peptides [13], indicating that the formation of 6HBs
was not completed at this point. These findings show that Env
remains vulnerable to inhibitors of 6HB formation and to
antibodies targeting gp41 intermediates throughout the fusion
reaction.
Our recent work revealed important differences between cell-
cell and virus-cell fusion models [15]. Whereas HIV-1 Env can
mediate cell fusion by merging two plasma membranes, the virus
itself fails to release its content at the cell surface. Instead, HIV-1
fuses with endosomes, presumably after undergoing CD4- and
coreceptor-mediated endocytosis. Time-resolved single virus
imaging showed that fusion with the plasma membrane was
blocked at a stage downstream of lipid mixing and did not progress
to productive entry. Importantly, endosomal fusion was markedly
delayed relative to virus internalization, demonstrating that the
surface exposure of gp41 intermediates is limited by the relatively
quick virus clearance from the cell surface. Endocytic HIV-1 entry
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peptides that target intermediate conformations of Env.
Disparate HIV isolates are known to exhibit a broad range of
sensitivities to C-peptides (e.g., [16]), but the mechanisms
underlying this differential sensitivity are not well understood.
Functional studies suggested a correlation between the potency of
a 34-residue long peptide, C34, and the propensity of Env to
expose the gp41 coiled coil domains upon binding to a soluble
CD4 (sCD4) [2,17,18]. The efficacy of C-peptides is also
modulated by their primary sequence and the sequence of
complementary N-HR domains that determine the binding
affinity [19,20]. However, the potency of C34 peptides derived
from HIV-1, HIV-2 and SIV isolates poorly correlated with their
propensity to form stable 6HBs with the complementary N-HR
domains [17].
Another determinant of the efficacy of C-peptides is thought to
be the window of opportunity for their binding to gp41
intermediates. This notion is based on correlation between the
kinetics of cell-cell fusion and the HIV-1 resistance to C-peptides
[9,10,17,18,21]. These findings led to a hypothesis that the gp41
residence time in pre-bundle conformations determines the HIV-1
sensitivity to C-peptides [9]. Implicit for this model is the inverse
relationship between the rate of fusion and the longevity of pre-
bundles and the slow, rate-limiting binding of C-peptides to these
intermediate conformations. The slow peptide binding would
require prolonged exposure of the gp41 coiled coil and would thus
limit its ability to block the quickly-progressing fusion. However,
since the HIV-1 fusion proceeds through intermediate steps at
which the gp41 coiled coils are not exposed, the overall kinetics of
fusion may not reflect the window of opportunity for the peptide
binding. Thus, in order to meaningfully examine the kinetic
determinants of the HIV resistance to C-peptides, one needs to
determine the actual residence time of gp41 in pre-bundle
conformations on the cell surface.
Endocytic entry of HIV-1 warrants careful examination of the
relationship between the rates of the surface-accessible pre-fusion
steps and the sensitivity to C-peptides. Here, we employed
inhibitors of distinct steps of HIV-1 fusion to monitor the
progression through CD4 and coreceptor binding steps followed
by productive endocytosis that protected the virus from fusion
inhibitors employed in this study. Using a simple kinetic model of
HIV fusion, we determined the rates of HIV-1 progression
through key pre-fusion intermediates and thus the residence times
of Env in these intermediates. Our results imply that multiple
factors contribute to the potency of C-peptides. An important
kinetic factor is the lifetime of gp41 pre-bundles which is defined
by the rate of engagement of a requisite number of receptors and
coreceptors on one hand and the productive virus endocytosis on
the other. We also found that viral determinants, such as the
extent of conformational changes in Env in response to the CD4
binding, significantly modulate the susceptibility of HIV-1 to C-
peptides. The ability to evaluate the HIV-1 residence time in
intermediate states permits rationalization of the complex
mechanisms that define the resistance to C-peptides and other
inhibitors targeting intermediate conformations of Env.
Results
Productive HIV-1 entry occurs through sequential CD4
and coreceptor binding followed by virus endocytosis
In order to directly monitor HIV-1 fusion with target cells, we
measured the cytosolic activity of the beta-lactamase-Vpr (BlaM-
Vpr) chimera packaged into the viral core [22]. Pseudoviruses
containing the reporter enzyme were bound to target cells in the
cold, and their fusion was initiated by quickly raising the
temperature to 37uC, as described in [15]. The BlaM activity
originates exclusively from viral cores delivered into the cytosol
through fusion, whereas cell-bound or internalized viruses do not
contribute to the signal [22]. Due to the low number of fused
viruses, an overnight incubation is required to accumulate
detectable amounts of cleaved fluorogenic BlaM substrate loaded
into the cytosol. In order to resolve the kinetics of HIV fusion that
occurs within a few hours (e.g., [23]), high concentrations of fusion
inhibitors were added at varied times of incubation at 37uC [15].
The acquisition of resistance to a membrane-impermeant inhibitor
yields the kinetics of virus progression beyond the step targeted by
that inhibitor. Alternatively, resistance to inhibitors targeting a late
step of fusion can occur through virus internalization that protects
it from external inhibitors and permits subsequent fusion with
endosomes.
The availability of inhibitors blocking distinct steps of HIV
entry enabled monitoring the progression through sequential
surface-accessible stages of fusion. The kinetics of CD4 binding
were monitored by time-of-addition experiments using a small-
molecule inhibitor BMS-806 [24,25]. Since the binding to CD4
renders HIV-1 resistant to this compound, escape from BMS-806
indicates the progression of fusion beyond the receptor-dependent
steps (Fig. 1B). The virtually complete inhibition of fusion by
BMS-806 added at the beginning of incubation shows that cell-
associated HIV-1 did not engage CD4 immediately following the
virus pre-binding protocol (30 min at 4uC). The rates of CXCR4
or CCR5 binding were measured by adding small-molecule
inhibitors AMD3100 and AD101, respectively.
The acquisition of resistance to C-peptides blocking the gp41
6HB formation has been traditionally interpreted as Env-mediated
fusion [3,4]. However, since HIV-1 fuses with endosomes of
HeLa-derived target cells [15], escape from C-peptides must occur
through virus uptake. The fact that HIV-1 escapes from
coreceptor antagonists before escaping from C-peptides (Fig. 1B)
implies that the fusion signal originates from viruses that engage
both CD4 and coreceptors prior to undergoing endocytosis. Note
Author Summary
The human immunodeficiency virus (HIV) envelope
glycoprotein (Env) mediates fusion between the viral and
cell membranes. The fusion is initiated by Env-receptor
interactions and is followed by coreceptor binding and
refolding of the transmembrane gp41 subunit. The gp41
refolding proceeds through several distinct intermediates,
culminating in the formation of a final helical bundle
structure which is blocked by inhibitory peptides targeting
the complementary domains of gp41. We have recently
shown that the exposure time of gp41 intermediates on
the cell surface is limited by productive HIV endocytosis
leading to fusion with endosomes. Here, we measured the
rates of progression of different HIV isolates through
distinct intermediate steps accessible to fusion inhibitors
and correlated these rates with the inhibitory potency of
peptides against these viruses. Whereas the potency of
peptides was proportional to the lifetime of gp41
intermediates on the cell surface, the baseline sensitivity
of the virus was also Env context-dependent. Higher
concentrations of these inhibitors were required to block
fusion induced by glycoproteins that were more resistant
to inactivation by the soluble receptor. Collectively, these
findings imply that both the kinetic factors and the
stability of Env-receptor complexes control the HIV
sensitivity to inhibitory peptides.
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internalized and degraded through CD4- and/or coreceptor-
independent pathways [26]. It is unlikely that HIV-1 acquires
resistance to these peptides by forming 6HBs prior to undergoing
endocytosis because: (i) fusion with the plasma membrane does not
progress beyond the lipid mixing stage [15]; and (ii) 6HB
formation occurs only after opening of a fusion pore [13]. Here,
we measured the rate of HIV-1 escape from C-peptides using a
recombinant 52-residue peptide, C52L, derived from the gp41 C-
HR domain [27]. In control experiments (data not shown) HIV-1
escape from the C52L peptide occurred at the same rate as escape
from the better characterized 34-residue peptide, C34.
In this work, we will be concerned only with the pre-fusion steps
occurring at the cell surface, which are key determinants of the
sensitivity to C-peptides and antibodies targeting intermediate
conformations of Env [9,10,18,28,29]. Once different HIV-1
isolates form ternary complexes with CD4 and coreceptors and
undergo endocytosis, subsequent fusion events appear to occur
with similar rates and efficiencies [15]. Thus, the fusion signal
measured by the time-of-addition protocol should reflect the rate
of cell surface-accessible steps of fusion.
A model for HIV-1 fusion
We sought to determine the residence time of HIV-1 in key
intermediate states and thus to evaluate the lifetime of gp41 pre-
bundles that are accessible on the cell surface to C-peptides and
neutralizing antibodies. To this end, we considered a minimal
kinetic model (Fig. 1C) that describes the virus association with the
cell surface followed by CD4 binding, coreceptor (CR) binding,
and, finally, by productive endocytosis. We operationally define
the following intermediate states the virus adopts sequentially
along its entry pathway: (i) the state (V) of the membrane-
associated virus which is sensitive to all three types of fusion
inhibitors; (ii) the state (VCD4) resistant to an inhibitor blocking the
HIV-CD4 binding, but sensitive to inhibitors of coreceptor
binding and 6HB formation; (iii) the state VCD4CR resistant to
inhibitors of receptor and coreceptor binding, but still sensitive to
inhibitors of 6HB formation; and (iv) the state VE resistant to all
three inhibitor types. The effective rate constants of transitions
between the successive states V, VCD4,V CD4CR and VE are
denoted by k1,k 2, and k3. Our model can be readily modified to
describe direct virus fusion with the plasma membrane by omitting
the endosomal fusion step and treating VE as the fusion state.
The model does not consider the reverse rates of CD4 and
coreceptor binding reactions. Moreover, the model makes no
assumptions about the stoichiometry of the receptor and
coreceptor binding. If several Env glycoproteins are involved in
HIV-1 entry, the virus must engage more than one pair of receptor
and coreceptor molecules in order to undergo fusion. In that case,
interactions with coreceptors at the virus-membrane contact may
start before the recruitment of a requisite number of CD4 is
completed. Then the VCD4 is a state where the receptor binding is
finalized while the coreceptor recruitment is still incomplete, so
that the transition to VCD4CR consists in the recruitment of the
missing coreceptors.
The model postulates that the viruses are subject to inactivation
characterized by the inactivation rate constants. Whereas the
general form of the model (see Fig. S4) accounts for different
inactivation rates at the sequential steps of the HIV-1 progression
along the fusion pathway, it is currently impossible to experimen-
tally determine the individual inactivation rates. Thus, in order to
evaluate the effective rate constants of fusion, we used a simplified
version of the model that assumes equal inactivation rate
constants, ki, for all stages of the fusion reaction. We also assume
Figure 1. Dissection of early steps of HIV-1 fusion with target
cells. (A) A schematic drawing showing HIV-1 entry via receptor-
mediated endocytosis followed by fusion with endosomes. Pathways
leading to virus degradation in lysosomes are shown by dashed lines.
CR denotes coreceptor. (B) Kinetics of surface-accessible steps of HIV-1
fusion with TZM-bl cells. HXB2 pseudoviruses were pre-bound to cells in
the cold and triggered to fuse by raising the temperature at time=0.
Inhibitors of CD4 binding (BMS-806), coreceptor binding (AMD3100)
and the 6-helix bundle formation (C52L) were added at varied times of
incubation to block the respective steps of fusion. The resulting extent
of fusion as a function of incubation time was measured by a BlaM
assay. The total virus uptake was measured by the fraction of pronase-
resistant viral p24 (see Materials and Methods). Error bars are SEM. (C) A
kinetic model of HIV fusion. The virus (V) progresses through CD4 and
coreceptor (CR) binding steps and undergoes endocytosis (VE) that
leads to fusion (VF). Stages of fusion sensitive to inhibitors, BMS-806,
AMD3100 (CXCR4 binding), AD101 (CCR5 binding), and C52L are
indicated by horizontal red lines. In this scheme, protection from C-
peptides occurs via receptor-mediated endocytosis, but not through 6-
helix bundle formation and fusion with the plasma membrane. Native
viruses and those that engage CD4 and CD4/coreceptor are assumed to
be inactivated with the rate constant ki, primarily due to a non-
productive endocytosis.
doi:10.1371/journal.ppat.1000585.g001
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endocytosis which is the predominant pathway of HIV-1 uptake
by HeLa-derived cells [15,26]. In other words, the total virus
uptake is assumed to reflect the rate of virus inactivation. This
non-productive pathway likely includes both CD4-independent
and CD4-mediated virus uptake which, in the absence of
coreceptor binding, does not lead to endosomal fusion.
The differential equations describing the virus evolution
through each of the states of the kinetic scheme (Fig. 1A, C) are
given in Appendix S1. The solution of these equations for the
number of viruses VE entering through productive endocytosis
(leading to endosomal fusion) as a function of time is given by:
VE~Vext{
k1:k2:k3:Vtot
(k2{k1):(k3{k1):(k1zki)
:exp½{(k1zki):t 
z
k1:k2:k3:Vtot
(k2{k1):(k3{k2):(k2zki)
:exp½{(k2zki):t 
{
k1:k2:k3:Vtot
(k3zki):(k3{k1):(k3{k2)
:exp½{(k3zki):t 
where Vext~
k1:k2:k3:Vtot
(k1zki):(k2zki):(k3zki)
Unlike the previously proposed models of Env-mediated fusion
[23,30], this model accounts for the effective lag before fusion.
This lag is given by 1/(k1?k2?k3?Vtot), where Vtot is the total
number of cell-bound fusion-competent viruses at time=0. Note
that Vtot cancels out upon normalizing data to the final extent of
fusion (see also Fig. S1), so that the kinetics of fusion do not depend
on the multiplicity of infection (MOI). Thus, normalization
eliminates the need to determine and/or control the exact number
of fusion-competent particles bound per cell. Our model describes
a wide variety of cell-cell and virus-cell fusion data using four free
parameters: k1,k 2,k 3 and ki. These effective rate constants can be
defined through the measurements of the kinetics of CD4 binding
(escape from BMS-806), coreceptor binding (escape from AD101
or AMD3100), the rate of productive endocytosis (escape from
C52L), and the rate of virus inactivation through non-productive
endocytosis (p24 uptake).
The knowledge of the kinetics of virus inactivation is important
because this process, along with the respective pre-fusion rate
constants, determines the exit rates from V, VCD4 and VCD4CR.
We thus obtained the ki by fitting a single exponential function to
the HIV p24 uptake data (Fig. 1B). A separate set of equations
(equations (10–12) of Appendix S1) was derived to describe the
kinetics of virus escape from CD4 and coreceptor binding
inhibitors and from C-peptides added at varied times of virus-
cell incubation. Through fitting of the solutions of these equations
to the respective data sets, we were able to determine the
remaining three rate constants k1,k 2 and k3 for the surface-
accessible steps of fusion (see the legend to Fig. 2 for details and
Table 1).
The lifetime of Env-CD4 complexes can be extended by
lowering the density or the affinity of coreceptors to Env
We first examined the progression of the primary R5-tropic
JRFL isolate through the surface-accessible fusion intermediates.
Pseudoviruses were produced and the incorporation and proteo-
lytic processing of JRFL Env was assessed by Western blotting (Fig.
S2). Viruses were pre-bound to target cells in the cold, and their
uptake and fusion were initiated by shifting to 37uC. Inhibitors of
Figure 2. Kinetics of JRFL fusion with target cells expressing
different levels of wild-type and mutant CCR5. (A) Fusion of JRFL
pseudoviruses with TZM-bl cells was measured by adding inhibitors of
distinct steps of this process (BMS-806, AD101 and C52L) at indicated
time points, as described in the legend to Figure 1B. (B) JRFL fusion with
HeLa-derived JC.10 cells expressing a low level of wild-type CCR5. (C)
JRFL fusion with JYN.2-15 cells expressing a high level of mutant (Y14N)
CCR5. Solid lines are the results of fitting the equations (10–12) of
Appendix S1 to experimental data. The inactivation rate, ki, was
determined by fitting a single-exponential function (dashed line) to the
p24 uptake data (crosses). The k1 was obtained by curve fitting the
expression (10) for the probability of VCD4 to the rate of escape from
BMS-806 (after entering the ki value and assigning arbitrary values to k2
and k3). The ki and k1 were then used to obtain k2 by fitting the
equation (11) for VCD4CR to coreceptor binding data. Finally, these three
rate constants were used to determine k3 through curve-fitting the
equation (12) for the probability of VE to the experimentally determined
rate of virus escape from C52L. The lines are color-coded according to
the symbols. Because the rates of JRFL escape from BMS-806 and
AD101 were identical when TZM-bl cells were used as targets (panel A),
only the CD4 binding curve (green line) is shown. Curve fitting was
done using the SigmaPlot Regression Wizard (SYSTAT Software, Inc.).
doi:10.1371/journal.ppat.1000585.g002
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incubation to obtain the kinetics of HIV-1 escape from these
inhibitors. As discussed above, HIV-1 acquires resistance to the
inhibitors of 6HB formation through receptor-mediated endocy-
tosis as opposed to fusion at the cell surface. Productive
endocytosis of this virus was thus measured by adding a high
concentration of the recombinant C52L peptide at varied time
points. In parallel experiments, the total virus uptake was
measured by the intracellular accumulation of the HIV-1 p24.
These measurements allowed us to determine the fusion and
inactivation rate constants for JRFL entry into different target
cells.
When HeLa-derived TZM-bl cells expressing high levels of
CD4 and CCR5 [31] were used as targets, JRFL engaged a
requisite number of CD4 and coreceptors with the virtually
identical kinetics (Fig. 2A). Thus, under these conditions, the
effective rate of CCR5 binding was too fast to be resolved. We
therefore sought to slow down the formation of ternary complexes
by reducing the density of CCR5 on the cell surface or by
diminishing its affinity to Env. A ,20-fold reduction of the
average number of CCR5 molecules per cell did not noticeably
affect the rate of coreceptor engagement (data not shown).
However, the kinetics of CCR5 binding and the final extent of
fusion were markedly diminished for JC.10 cells [31] expressing a
,100-fold lower number of CCR5 compared to TZM-bl cells
(Fig. 2B). We were thus able to kinetically resolve the CCR5
binding step and measure its effective rate constant, k2 (Table 1).
Next, we examined the impact of the coreceptor binding affinity
on the rate of the ternary complex formation. JRFL pseudoviruses
were bound and fused with JYN.2-15 cells [32] expressing high
levels of wild-type CD4 and the Y14N CCR5 mutant similar to
those present on TZM-bl cells. JRFL fusion with these cells was
less efficient and was highly sensitive to inhibition by AD101
(Table 2), in agreement with the diminished affinity to gp120
caused by the loss of the critical Tyr14 residue at the CCR5 N-
terminus. As expected, the Y14N mutation reduced the kinetics of
virus escape from AD101, whereas the rate of CD4 binding
remained unchanged (Fig. 2C and Table 1). Together, these
results demonstrate that the lifetime of Env-CD4 complexes on the
cell surface can be manipulated by changing the density of
coreceptors or their binding affinity to gp120.
Increased coreceptor binding affinity in the context of X4
Env accelerates the coreceptor engagement but not HIV-
1 endocytosis
Next, we compared the kinetics of surface-accessible steps of
fusion induced by JRFL Env and by the laboratory adapted HXB2
Env. These glycoproteins differ in many aspects, including the
coreceptor tropism and sensitivity to neutralizing antibodies and
C-peptides [18,33,34]. HXB2 pseudoviruses engaged CD4 faster
than JRFL (Figs. 2A and 3A), in agreement with the enhanced
receptor binding affinity associated with the HIV-1 adaptation to
growth in culture [5,35,36]. By contrast, HXB2-CD4 complexes
became protected from the coreceptor binding inhibitor at a much
slower rate than JRFL. The different kinetics of coreceptor binding
are consistent with the vastly different coreceptor binding affinities
of laboratory adapted X4 and primary R5 Env glycoproteins
[37–39]. The ,10-fold higher CCR5 expression on TZM-bl cells
compared to the CXCR4 expression [31,40] did not seem to be
responsible for the more rapid CCR5 engagement, since the rate
of this coreceptor binding was not noticeably affected by the 10-
fold reduction in its expression level (data not shown). Interest-
ingly, HXB2-CD4-coreceptor complexes were internalized at a
,3-fold faster rate compared to the ternary JRFL complexes (k3
constant, Table 1), whereas the rates of bulk endocytosis leading to
virus degradation were close for these viruses (Figs. 2A and 3A,
crosses). As a result of the above compensatory variations in the
rate constants of pre-fusion steps, the overall kinetics of JRFL and
HXB2 escape from C52L were close. This result is in contrast with
the faster kinetics of cell-cell fusion induced by JRFL compared to
HXB2 Env [18].
We next assessed the effect of coreceptor binding affinity in the
context of X4 Env. Toward this goal, we used a chimeric HXB2
Env in which the V3 loop was substituted with that of the R5-
tropic BaL isolate [41]. This chimera, hereafter referred to as
V3BaL, exclusively utilizes CCR5 for fusion and appears to bind
CCR5 with high affinity [21,41]. This notion is consistent with our
data showing that V3BaL fuses with target cells expressing the low-
affinity CCR5 mutants (Fig. S3A) and with cells expressing low
density of CCR5 (data not shown). Moreover, V3BaL was even
somewhat more resistant to AD101 than BaL and JRFL (Table 2).
After verifying that HXB2, V3BaL and BaL Env were
proteolytically processed and incorporated into pseudoviruses at
similar levels (Fig. S2), we compared the kinetics of fusion mediated
by these glycoproteins. As expected, the rates of CD4 binding by
V3BaL and HXB2 were indistinguishable (Fig. 3A, B and Table 1),
whereas the V3BaL-CCR5 binding was ,3-fold faster than HXB2-
CXCR4 binding. This result is consistent with the high affinity of
the chimera to CCR5 and with the higher expression of CCR5 on
TZM-bl cells compared to endogenous expression of CXCR4. In
spite of the faster rate of ternary complex formation, the subsequent
internalization of V3BaL-CD4-coreceptor complexes was ,2-fold
Table 1. Effective rate constants of HIV-1 fusion and
inactivation.
Virus Cells ki (min
21)k 1 (min
21)k 2 (min
21)k 3 (min
21)
JRFL TZM-bl 0.0660.01* 0.0360.01 .100 0.0960.03
JYN.2-15 0.0460.02 0.0460.01 0.0760.02 0.1760.05
JC.10 0.0460.04 0.0260.01 0.0560.02 0.1060.04
HXB2 TZM-bl 0.0560.01 0.0960.01 0.1560.02 0.2560.04
BaL TZM-bl 0.0360.02 0.01160.004 .100 .100
V3BaL TZM-bl 0.0560.01 0.0960.01 0.4860.1 0.1360.04
*Standard error of the curve fit.
doi:10.1371/journal.ppat.1000585.t001
Table 2. HIV-1 sensitivity to inhibition by AD101 and C34.
Viruses Cells IC50 AD101 (nM) IC50 C34 (nM)
JRFL TZM-bl 390687* 1563( 8 61***)
JC10 ND** 761
JYN.2-15 ,0.1 862
HXB2 TZM-bl 1.660.2
JYN.2-15 5.160.2
BaL TZM-bl 170633 861
V3BaL TZM-bl 7106207 2.360.3
JYN.2-15 ND 1.760.2
*Standard error of the curve fit.
**ND, not determined.
***IC50 for the C34JRFL peptide.
doi:10.1371/journal.ppat.1000585.t002
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kinetics of the HXB2 and V3BaL pre-fusion steps resulted in similar
overall rates of escape from C52L.
To better understand the differences in the progression of
HXB2 and V3BaL through surface-accessible steps of fusion, we
examined the fusion of viruses pseudotyped with wild-type BaL
Env. BaL exhibited markedly different kinetics of fusion compared
to HXB2 and V3BaL (Fig. 3). First, BaL engaged CD4 ,3-fold
slower than JRFL and almost 9-fold slower than HXB2 (Table 1).
By contrast, BaL escaped from AD101 and from C52L at rates
that were indistinguishable from the rate of CD4 binding. The
unusually quick BaL protection from C52L prompted us to
examine whether this effect was due to the direct fusion with the
plasma membrane as opposed to productive endocytosis demon-
strated for JRFL and HXB2 viruses [15]. We therefore compared
the rates of virus escape from C52L and from the temperature
block applied at varied times of BaL incubation with TZM-bl cells
(see [15] and Fig. S3B). A marked delay between the BaL escape
from the temperature block compared to its escape from the
peptide inhibitor strongly implies that this virus also fuses with
endosomes. Collectively, these data show that BaL engages CD4
slowly but then completes the CCR5 binding and enters endocytic
compartments at an unusually high rate.
The lifetime of gp41 pre-bundles can be obtained from
the rates of coreceptor engagement and productive
endocytosis
Having determined the effective rate constants of progression
through the CD4 and coreceptor binding steps for different Env
glycoproteins and target cells (Table 1), we used the equations (6–8)
of Appendix S1 to calculate the probability of finding the virus in
VCD4,V CD4CR and VE states as a function of time (Fig. 4A–D). We
then determined the time averages of HIV-1 in these states by
integrating the equations (6) and (7) from time=0 to the end of
virus-cell incubation and dividing over this time interval (the
resulting equations (13) and (14) are given in Appendix S1). The
time averages of different HIV-1 in VCD4 and VCD4CR and the
combined residence times in both states are shown in Fig. 4E.
The gp41 pre-bundles are formed upon the Env binding to
CD4 or both CD4 and coreceptors [2–4] and are cleared from the
cell surface by endocytosis [15]. Thus, the ability to determine the
time spent in VCD4 and VCD4CR states provided an opportunity to
estimate the lifetimes of pre-bundles on the cell surface. The
shortest apparent exposure of pre-bundle intermediates was
observed for BaL, whereas the longest combined time in VCD4
and VCD4CR was observed upon JRFL fusion with cells expressing
the low-affinity CCR5 mutant (Fig. 4E). Since C-peptides target
the gp41 coiled coils, we asked whether their inhibitory potency
correlated with the lifetime of these intermediates on the cell
surface. It has been proposed that the longevity of pre-bundles
determines the HIV-1 sensitivity to C-peptides [9]. However, this
notion was based on correlation between the peptide’s potency
and the overall kinetics of HIV Env-mediated cell-cell fusion and
not on measurements of the actual lifetime of gp41 coiled coils in
the context of virus entry. In order to rationalize the kinetic
determinants of HIV-1 sensitivity to C-peptides, we sought to
compare the time spent in pre-bundle intermediates with the
inhibitory potency of these peptides.
HIV-1 resistance to C-peptides does not correlate with
the rate of productive endocytosis
To determine the susceptibility of different HIV-1 Env to
inhibition by C-peptides, we measured virus-cell fusion in the
Figure 3. Progression of the HXB2, V3BaL and BaL through
surface-accessible stages of fusion. (A) The kinetics of HXB2
binding to CD4 and CXCR4 was determined by the time-of-addition
experiments using BMS-806 and AMD3100 (see also Fig. 1B), and the
rate of productive endocytosis was measured by adding C52L. (B, C) The
rates of CD4 and CCR5 engagement by V3BaL (B) and BaL (C) were
determined by adding BMS-806 and AD101, respectively. The kinetics of
receptor-mediated virus endocytosis was measured by escape from
C52L. In all panels, the bulk HIV-1 uptake was determined by
accumulation of the intracellular p24 (cyan crosses) and fitted with a
single-exponential function (dashed lines). The solid lines were
obtained by curve fitting the model equations to experimental points,
as described in the text and in the legend to Figure 2. Since all early
steps of BaL fusion occurred virtually simultaneously, only one
theoretical curve is shown in panel C.
doi:10.1371/journal.ppat.1000585.g003
Kinetics of HIV-Cell Fusion
PLoS Pathogens | www.plospathogens.org 6 September 2009 | Volume 5 | Issue 9 | e1000585presence of the well-characterized C34 peptide [19]. JRFL
exhibited the highest resistance to this peptide while BaL was
somewhat more susceptible to inhibition (Fig. 5A, Table 2). By
comparison, HXB2 and V3BaL were much more potently
inhibited by C34 with the chimera being only marginally more
resistant than the wild-type HXB2. So, in the context of HXB2
Env and under our experimental conditions, the coreceptor
tropism and the coreceptor binding affinity had a modest effect on
the virus’ resistance to C34. Similar results were obtained with the
C52L peptide (data not shown).
The 10-fold difference between the IC50 for JRFL and HXB2 by
C34 is in stark contrast with the comparable rates of their escape
from high doses of C-peptides due to productive endocytosis
(Figs. 2A and 3A). Plotting the IC50 values against the half-times of
HIV-1 escape from C52L, as determined from the measurements
shown in Figs. 2 and 3, confirmed that the C34 potency did not
correlate with the rate of virus protection from this inhibitor
(Fig. 6A). In contrast to these results, the kinetics of cell-cell fusion
appears to inversely correlate with the potency of C-peptides [9].
These seemingly discrepant findings likely stem from the fact that
HIV-1 escape from inhibitory peptides does not reflect virus-cell
fusion, but rather corresponds to productive endocytosis.
Another possibility is that the C34 peptide used in our
experiments had different affinity to the gp41 N-HR domains of
HIV-1 isolates examined in this work. The conventional C34
peptide is derived from the gp41 C-HR of the IIIB clone [17,19],
Figure 4. Kinetics of HIV-1 progression through intermediate states and the residence times in these states. (A–D) The probabilities of
finding the virus in CD4-bound (VCD4) and coreceptor-bound (VCD4CR) states and of undergoing receptor-mediated endocytosis (VE) as a function of
time were obtained by entering the respective rate constants (Table 1) into the equations (6–8). (E) Time averages for HIV-1 in the CD4-bound and
coreceptor-bound states were determined from equations (13) and (14), using the respective rate constants. The total time averages of HIV-1 in
intermediate stages prior to undergoing endocytosis (the sum of VCD4 and VCD4CR) are shown by open bars.
doi:10.1371/journal.ppat.1000585.g004
Kinetics of HIV-Cell Fusion
PLoS Pathogens | www.plospathogens.org 7 September 2009 | Volume 5 | Issue 9 | e1000585which isidenticaltothe respectivedomainsof HXB2gp41 but notof
JRFL gp41 (Fig. 5D). Since the C34 sequence has been shown to
affect its potency against HIV and SIV isolates [17], we asked if the
JRFL-derivedC34(designatedC34JRFL)isamorepotentinhibitorof
fusionthantheC34IIIB.Bo thC3 4 IIIBand C34JRFL potentlyinhibited
HXB2 fusion at comparable concentrations (Fig. 5B). Even though
JRFLwasapproximately2-foldmoresensitivetoitsownC34thanto
C34IIIB, still higher doses of the former peptide were required to
block JRFL fusion compared to HXB2 fusion. Thus, neither the
kinetics of virus escape from C-peptides nor the sequences of C34
can fully account for the greater resistance of JRFL to this inhibitor.
The above results highlight the importance of measuring the actual
lifetime of gp41 pre-bundles (Fig. 4) in order to better rationalize the
kinetic factors controlling the HIV-1 resistance to C-peptides.
Kinetic determinants of HIV-1 resistance to C-peptides
We asked whether the time averages of VCD4 and VCD4CR states
are predictive of the virus’ sensitivity to C-peptides. When the
potency of C34 was plotted against the time spent in VCD4
(Fig. 6B), the points clearly fell into two groups – JRFL fusion with
different target cells and HXB2/BaL/V3BaL fusion with TZM-bl
cells. Within these two groups, the IC50 correlated well with the
time average in VCD4. Thus, in the context of JRFL Env or
HXB2/BaL Env, the diminished rate of coreceptor engagement
and thus the increased lifetime of early gp41 intermediates were
associated with enhanced sensitivity to C34. In contrast, we saw no
apparent correlation between the lifetime of VCD4CR and the
potency of this peptide (Fig. 6C). This was surprising because the
gp41 coiled coils should be better exposed to the peptide at
VCD4CR compared to VCD4 [2].
Since the HXB2 (and likely V3BaL) coiled coils are exposed as
early as upon CD4 binding [2–4] and should thus persist
throughout the surface-accessible steps of fusion, a more
meaningful parameter for characterizing the window of opportu-
nity for the C34 binding is the total time spent in VCD4 and
VCD4CR states. This parameter should also adequately describe the
Figure 5. HIV-1 inhibition by the C34 peptide and inactivation by soluble CD4. (A) Viruses were pre-bound to TZM-bl cells and allowed to
fuse for 90 min in the presence of varied concentrations of C34 derived from the HIV-1 IIIB strain. The solid lines were obtained by curve fitting
experimental data using the following equation: Fusion=1/(1+[C34]/IC50), where [C34] is the C34 concentration (see Table 2 for the IC50 values). (B)
Viruses were fused with TZM-bl cells in the presence of different concentrations of C34 derived from either IIIB or JRFL gp41 (denoted C34IIIB and
C34JRFL, respectively). (C) HIV-1 inactivation by different doses of soluble CD4 was carried out as described in Materials and Methods. (D) Amino acid
sequences of the C34 peptide derived from the IIIB/HXB2, JRFL and BaL gp41. The error bars are SEM of at least three independent measurements.
doi:10.1371/journal.ppat.1000585.g005
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JRFL coiled coils are optimally exposed only after engaging both
CD4 and CCR5 [2], the total time in VCD4 and VCD4CR states is
dominated by the latter intermediate (Fig. 4C and E). We found
that the combined residence time in these states inversely
correlated with the IC50 for C34 (Fig. 6D). As in the Fig. 6B,
this correlation was more apparent when fusion of the V3 loop-
swapped constructs (BaL, HXB2 and V3BaL) and JRFL fusion
with different cells were considered separately. These data suggest
that, in the context of the same Env backbone, the total time spent
in VCD4 and VCD4CR is a good predictor of the C34’s potency.
The extent of Env inactivation by soluble CD4 correlates
with its sensitivity to C-peptides
The lifetime of the gp41 coiled coils did not fully account for the
differences in the inhibitory potency of C34. Indeed, the quick
progression of BaL through the surface-accessible pre-fusion steps
suggests that the gp41 coiled coils are very briefly exposed prior to
entering into endosomal compartments. However, whereas BaL
was much more resistant to C34 than HXB2 (Table 2), it was
more susceptible to this inhibitor than JRFL, which spent much
longer time in pre-bundle intermediates than BaL. Thus, virus
strain-specific factors appear to contribute to the baseline
sensitivity of HIV-1 to C-peptides. In addition, the modest effect
of the HXB2 V3 loop substitution on the potency of C34 indicates
that critical determinants of the virus’ resistance reside outside the
V3 loop. Envelope glycoproteins of laboratory adapted strains are
generally less stable and tend to inactivate upon binding to CD4
[42–44]. It is thus possible that the degree to which different Env
glycoproteins refold in response to the CD4 binding could
determine the sensitivity to C-peptides [17]. Recent study implies
that this inactivation occurs via CD4-induced conformational
changes in Env and not due to the gp120 shedding [45]. This work
also demonstrates the strain-dependent differences in the exposure
of the gp41 coiled coils caused by sCD4 binding.
To assess the extent of irreversible Env refolding in response to
receptor binding, we measured to degree of virus inactivation
Figure 6. Correlation between the potency of C34 and the time average of HIV-1 in intermediate states. (A) Relationship between the
C34 IC50 (normalized to that of JRFL on TZM-bl cells) and the kinetics of escape from a high concentration of C52L parameterized as the time at which
half of the viruses acquire resistance to this peptide. Solid line is a linear regression. (B) The C34 IC50 was normalized to that for the JRFL fusion with
TZM-bl cells and plotted vs. the time average in the VCD4 state. Separate linear regressions are shown for JRFL fusion with different target cells (dotted
line, r
2=0.99) and for HXB2-BaL-V3BaL constructs fusing with TZM-bl cells (dashed line, r
2=0.73). (C) Lack of correlation between the inhibitory
activity of C34 and the lifetime of the VCD4CR state. (D) Correlation between the time averages in both intermediate stages (VCD4 plus VCD4CR) and the
potency of C34. Separate linear regressions are shown for BaL, HXB2 and V3BaL (dashed line, r
2=1.00) and for JRFL fusion with different target cells
(dotted line, r
2=0.93). The IC50 for the C34JRFL against JRFL (star) is shown for comparison. Note that the more potent C34JRFL peptide inhibited JRFL
almost as efficiently as the C34IIIB inhibited BaL (Table 2).
doi:10.1371/journal.ppat.1000585.g006
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varied concentrations of sCD4, and the remaining fusion activity
was determined after an additional 90 min-incubation with
TZM-bl cells. These experiments revealed that JRFL was the
most resistant to sCD4, BaL showed an intermediate sensitivity,
whereas V3BaL and HXB2 were both strongly inactivated under
these conditions (Fig. 5C). The similar effect of sCD4 on HXB2
and V3BaL viruses was as expected for Env glycoproteins sharing
t h es a m eb a c k b o n e .
Notably, the extents of sCD4-induced inactivation and
inhibition by C-peptides ranked similarly (Fig. 5A and C). This
result is consistent with the notion that the stability of Env-CD4
complexes determines the extent of exposure of the gp41 coiled
coil. In other words, for the same time spent in a pre-bundle
conformation, the sensitivity to C-peptides appears to depend on
the extent of conformational changes in Env occurring in response
to the receptor binding. This model is supported by the different
efficacies of C34 against HXB2 fusing with TZM-bl and JRFL
fusing with JC.10 cells in spite of the similar lifetimes of gp41 pre-
bundles (Fig. 6D). Together, our results reveal a complex interplay
between the Env stability (viral determinants) and the rate of
progression through surface-accessible intermediates (viral and
cellular determinants) in defining the HIV-1 resistance to C-
peptides.
Discussion
In the present work, we characterized the HIV-1 progression
through surface-accessible steps of entry prior to virus uptake and
fusion with endosomes. Through measuring the rates of escape
from membrane-impermeant inhibitors blocking distinct pre-
fusion steps, we were able to determine the residence times in
intermediate states in which HIV-1 recruited a requisite number
of CD4 or both CD4 and coreceptors. This analysis revealed the
viral strain-dependent and target cell-dependent differences in the
average times the HIV-1 spent in distinct intermediates on the cell
surface. The knowledge of the HIV-1 progression through the pre-
fusion steps permitted the rationalization of the inhibitory potency
of C-peptides targeting the gp41 coiled coils. We found that, unlike
the Env-mediated cell-cell fusion, the time-course of HIV-1 escape
from inhibitors of 6HB formation poorly correlated with the
resistance to C34 (Fig. 6A). This could be due to the different rates
of productive virus endocytosis that, in addition to the kinetics of
CD4 and coreceptor engagement, control the time of exposure of
the gp41 coiled coils on the cell surface.
Quantitative analysis of the HIV-1 fusion kinetics revealed
correlation between the total residence time in pre-bundle
conformations and the potency of C34. Interestingly, the lifetime
of the VCD4, but not of VCD4CR, was predictive of the virus’
sensitivity to this inhibitor. This result was unexpected because the
gp41 coiled coils should be better exposed to C-peptides at the
latter state [2]. The previously proposed model [9] posits that the
C-peptide binding to the complementary coiled coil domain is
slow and thus occurs optimally upon prolonged exposure of these
domains. However, our data suggest that the peptides can
effectively bind to relatively short-lived gp41 intermediates
(Fig. 6B). The observation that C-peptides cause closure of
nascent fusion pores shortly after their addition to fusing cells [13]
also supports the notion that the peptide binding occurs on a
shorter time scale than the average lifetime of a pre-bundle
intermediate (several minutes). We surmise that the quick peptide
binding to the stably exposed coiled coils can account for the lack
of correlation between the lifetime of ternary complexes and the
potency of C34 (Fig. 6C). On the other hand, the enhanced
potency of C34 associated with the longer-lived VCD4 indicates
that the coiled coil exposure at this point is not completed.
Our findings are in agreement with the previous reports that
multiple factors control the HIV-1 resistance to C-peptides
[17,20]. First, the baseline sensitivity of diverse Env glycoproteins
appears to be determined by their propensity to undergo
irreversible conformational changes upon engaging CD4. The
exceptionally high resistance of JRFL to C-peptides in spite of the
long time spent in CD4/coreceptor-bound state could be due in
part to a restricted exposure of its coiled coils [2]. Second, the C-
peptide’s primary sequence, which affects their binding affinity to
the gp41 coiled coil, appears to modulate their inhibitory potency.
Third, our results show that kinetic factors determine the longevity
of gp41 pre-bundles and thus control the potency of C-peptides.
The window of opportunity for the C-peptide binding depends on
cellular factors, such as the density of coreceptors and their affinity
to Env, as well as on the rate of receptor-mediated virus
endocytosis. We surmise that the faster rate of productive
endocytosis in certain cell types may diminish the gp41 pre-
bundle exposure and protect the virus from C-peptides and
antibodies targeting Env intermediates.
Clearly, a full quantitative description of HIV-1 fusion awaits
the determination of the fusion stoichiometry, as well as the
identification of intracellular steps and factors involved in virus
entry. However, experimental strategies developed in this work
provide a means to evaluate the kinetics of surface-accessible steps
of HIV-1 fusion. Our data show that the rate of progression
through pre-fusion steps is a critical determinant of the virus’
susceptibility to C-peptides and likely to neutralizing antibodies
targeting CD4-induced epitopes. Further studies involving a larger
set of primary and laboratory adapted HIV strains are needed to
substantiate the conclusions of this work and to define the viral and
cellular determinants of resistance to peptide inhibitors.
Materials and Methods
Cells and reagents
HeLa-derived JC.10 [31], JYN.2-15, and JGR.H11 [32] cells
were a gift from Dr. D. Kabat (OHSU, OR). TZM-bl cells were
obtained from NIH AIDS Research & Reference Reagent
Program and grown in Dulbecco modified Eagle medium
(DMEM, Invitrogen, Carlsbad, CA) supplemented with 10% fetal
bovine serum (FBS, HyClone Laboratories, Logan, UT) and
penicillin-streptomycin (Invitrogen). 293T/17 cells (ATCC, Man-
assas, VA) were grown in DMEM/10% FBS, 0.5 mg/ml
Geneticin (Invitrogen), and penicillin-streptomycin. The pCAGGS
plasmids encoding JRFL or HXB2 Env [46] were provided by Dr.
J. Binley (Torrey Pines Institute, CA). The pCAGGS plasmids
encoding HXB2-BaL chimera Env in V3 loop, V3BaL, were
constructed by replacing of Env coding sequence of pSV7D HXB
BaL, a gift from Dr. R. Doms (University of Pennsylvania). HIV-1
BaL.01 [47] Env expression vector was obtained from NIH AIDS
Research & Reference Reagent Program. The HIV-1 based
packaging vector pR8DEnv lacking the env gene was from Dr. D.
Trono (University of Geneva, Switzerland). Soluble CD4 was
purchased from Progenics (Tarrytown, NY). The C52L recombi-
nant peptide [27] was a gift from Dr. Min Lu (Cornell University).
BMS-806 [24,25] was synthesized by ChemPacific Corp.
(Baltimore, MD), AMD3100 [48] and pronase were purchased
from Sigma (St. Louis, MO), and AD101 [49] was a gift from Dr.
J. Strizki (Schering Plough, Kenilworth, NJ). The C34IIIB peptide
was synthesized by Dr. L-X. Wang (IHV, University of Maryland)
and the JRFL gp41-derived C34 peptide (Ac-WMEWEREID-
NYTSEIYTLIEESQNQQEKNEQELL-NH2) was kindly provid-
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these peptides was .98%, as determined by HPLC.
Virus preparation
Pseudoviruses containing the b-lactamase-Vpr (BlaM-Vpr) were
produced as described in [15]. Briefly, 293T/17 cells on a 60 mm
dish were transfected by Ca-phosphate protocol with 10 mg
pR8DEnv, 5 mg pMM310 vector expressing BlaM-Vpr [50], 4 mg
pcRev [51], and 15 mg pCAGGS encoding JRFL, HXB2,
or V3BaL Env, or pHIV1 BaL.01 (expressing BaL Env). The
infectious titer was determined by a b-Gal assay in TZM-bl
cells [52].
Virus-cell fusion assay
Measurements of HIV-1 fusion with target cells were carried
out essentially as described previously [15]. Briefly, viruses bearing
the BlaM-Vpr chimera were bound to TZM-bl cells by
centrifugation at 20956g, 4uC for 30 min. After washing off
unbound viruses, cells were incubated at 37uC for 90–120 min. At
indicated times of incubation, the fusion reaction was stopped by
adding specific inhibitors of CD4 binding (10 mM of BMS-806),
coreceptor binding (5 mM of AMD3100 or 7 mM of AD101), or
inhibitors of 6-helix bundle formation (1 mM of C52L). The
concentration of a given entry inhibitor used in these time-of-
addition experiments exceeded the fully inhibitory concentration
(determined in separate experiments) by at least 3-fold. Samples
were then loaded with the BlaM substrate CCF2-AM (Gene-
BLAzer in vivo detection kit, Invitrogen) on ice and incubated at
20uC for 12 hr. The resulting fluorescence signals at 460 nm (blue)
and 528 nm (green) were measured using the Synergy HT plate
reader (Bio-Tek Instr., Germany). The dose-response dependence
for HIV fusion in the presence of inhibitors was obtained by pre-
binding viruses to cells, as above, and incubating at 37uC for
90 min with various concentrations of C34 prior loading cells with
the BlaM substrate.
Virus internalization assay
Cells (3?10
4 cells/well in 96-well plates) were grown overnight in
regular medium. Virions were added to cells (MOI 0.7) and
centrifuged as described above. After washing to remove unbound
viruses, cells were incubated at 37uC for varied times in the
presence of 1 mM of C52L to prevent fusion. At defined time
points, virus uptake was stopped and the external virus was
stripped off by treatment with 2 mg/ml pronase on ice for 10 min.
After washing with DMEM/10% serum, cells were lysed and the
amount of p24 in cell lysate was determined using a p24 ELISA
Kit (PerkinElmer Life Sciences Inc, Boston, MA).
Virus inactivation by soluble CD4
Twenty ml aliquots of 10-fold concentrated viral preparations
were pre-incubated for 30 min at 37uC with different concentra-
tions of sCD4. Following the incubation, the mixture was diluted
10-fold with the growth medium and added to TZM-bl cells (final
MOI=0.8 in the absence of sCD4). Virus binding to cells was
augmented by centrifugation at 4uC, as described above. Cells
were washed to remove unbound viruses, and fusion was initiated
by shifting to 37uC for 90 min, after which time the process was
stopped by reducing the temperature. The BlaM signal was
normalized to that obtained for mock-treated viruses.
Supporting Information
Figure S1 The normalized kinetics of fusion is independent of
the number of cell-bound viruses. JRFL viruses were added to
TZM-bl cells at the multiplicity of infection (MOI) 1 or 0.2. After
pre-binding the viruses at 4uC, cells were washed and shifted to
37uC to induce fusion. (A) The kinetics of BlaM signal for the two
different MOI is shown. (B) The kinetics of fusion after
normalizing the data to the last time point. Even though the
overall BlaM signal is proportional to the MOI, the rate of fusion
is independent of the virus input.
Found at: doi:10.1371/journal.ppat.1000585.s001 (0.37 MB TIF)
Figure S2 Processing and incorporation of various HIV-1 Env
glycoproteins into pseudoviruses assessed by Western blotting.
Viral lysates were prepared with RIPA lysis buffer (0.05 M
T r i s C l ,0 . 1 5MN a C l ,1 %T r i t o nX - 1 0 0 ,0 . 1 %s o d i u md o d e c y l
sulfate (SDS) and 1% sodium deoxycholate) that contained the
Complete protease inhibitor (Roche Applied Science, Mannheim,
Germany). The samples were separated on a 10% SDS-PAGE gel
and transferred to PVDF membrane (Millipore, Billerica, MA).
The viral proteins were then detected with anti-b-lactamase
monoclonal antibody (QED Bioscience Inc, San Diego, CA), anti-
p24 sera (from AIDS Research and Reference Reagent Program),
and anti-gp120 polyclonal antibody (Fitzgerald, Concord, MA).
The blot was treated with biotinylated anti-mouse or rabbit
immunoglobulin (GE Healthcare Bio-Sciences AB, Uppsala,
Sweden), or anti-goat immunoglobulin (Sigma) as the secondary
antibody and then incubated with streptavidin-horseradish
peroxidase conjugate (GE Healthcare Bio-Sciences). Chemilumi-
nescence from the protein bands was visualized on the Fluor
Chem SP (Alpha Innotech, San Leandro, CA) using the Lumi-
Light
plus (Roche) substrate.
Found at: doi:10.1371/journal.ppat.1000585.s002 (1.04 MB TIF)
Figure S3 Fusion with target cells expressing mutant CCR5 and
escape from C52L and the temperature block. (A) The efficacy of
JRFL, HXB2, BaL and V3BaL fusion with HeLa cells expressing
similar levels of CD4, CXCR4 and wild-type (TZM-bl) or mutant
(JYN.2-15 and JGR.H11) CCR5. In these experiments, the viral
input was normalized by inoculating the cells with the same
amount of virus (an equivalent of MOI 0.7 for TZM-bl cells). Note
that BaL failed to fuse with cells expressing the Y14N CCR5 and
fused inefficiently with cells expressing the G163R mutant. The
ability of V3BaL to utilize the Y14N CCR5 mutant is consistent
with the less pronounced dependency of X4-tropic viruses on the
N-terminal segment of their cognate coreceptor. (B) BaL or JRFL
pseudoviruses were bound to TZM-bl cells in the cold and induced
to fuse by shifting to 37uC. The fusion was stopped at indicated
times either by adding 1 mM C52L or by briefly placing cells on
ice. Cells were then loaded with the BlaM substrate and incubated
overnight at 13.5uC, a temperature that prevented HIV fusion but
allowed the cleavage of the BlaM substrate.
Found at: doi:10.1371/journal.ppat.1000585.s003 (0.46 MB TIF)
Figure S4 Simulation of the effect of changes in k2 and ki on
the fusion kinetics. (A) A model of HIV fusion in which the
equality requirement for the inactivation rate constants at
different stages of fusion has been relaxed. Thus, in addition to
k1,k 2 and k3 constants, the reaction is described by three
inactivation rate constants, ki0,k i1 and ki2.( B )M o d e l i n gt h e
fusion kinetics using the rate constants similar to those obtained
for V3BaL fusion (see Table 1). (C, D) Changes in the kinetics of
the escape from C-peptides due to an 8-fold increase in k3 or ki2,
respectively.
Found at: doi:10.1371/journal.ppat.1000585.s004 (0.66 MB TIF)
Appendix S1
Found at: doi:10.1371/journal.ppat.1000585.s005 (0.08 MB
DOC)
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